Search

Your search keyword '"Pinter T"' showing total 114 results
Start Over Author "Pinter T"
Sorry, I don't understand your search. ×
114 results on '"Pinter T"'

7. 203P Randomized study of single-agent metronomic versus weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with HR+/HER2- advanced breast cancer

Author

Cazzaniga, M.E., primary, Martinez Jañez, N., additional, Kukielka-Budny, B.D., additional, Ulanska, M., additional, Bourgeois, H., additional, Muñoz Mateu, M., additional, Morales Murillo, S., additional, Bayo, J., additional, Cortesi, L., additional, Pinter, T., additional, Palacova, M., additional, Cherciu, N., additional, Petru, E., additional, Ettl, J., additional, De Almeida, C., additional, Raymond, R., additional, Villanova, G.R., additional, Thanh Minh, C. Ta, additional, Rodrigues, A.C.F., additional, and Freyer, G., additional

Published
2021
Full Text
View/download PDF

10. Overlap of coronary disease and pulmonary arterial hypertension in systemic sclerosis

Author

Komocsi, A., Pinter, T., Faludi, R., Magyari, B., Bozo, J., Kumanovics, G., Minier, T., Radics, J., and Czirjak, L.

Subjects
Pulmonary hypertension -- Diagnosis, Pulmonary hypertension -- Development and progression, Pulmonary hypertension -- Research, Coronary heart disease -- Diagnosis, Coronary heart disease -- Development and progression, Coronary heart disease -- Research, Scleroderma (Disease) -- Complications and side effects, Scleroderma (Disease) -- Research, Systemic scleroderma -- Complications and side effects, Systemic scleroderma -- Research, Blood flow -- Measurement, Blood flow -- Research, Cardiac catheterization -- Patient outcomes, Cardiac catheterization -- Research, Health
Published
2010

12. The Role of Online Bible Readers in Biblical Concordance Making

Author

Pintér Tibor M. and Márkus Katalin P.

Subjects
bible translations, bible concordances, terminology, online bible readers, History of Central Europe, DAW1001-1051, Language and Literature
Abstract

Bible concordances lead Bible readers with rendering words and phrases of the Holy Bible in alphabetical listings and show where the terms occur throughout all books of Scripture. With cross-references for verses, concordances make it easy to understand the meaning of terms and the context in which those words are used. In Hungarian Bible studies several translations of the Bible are available (also online) and some of the contemporary translations are provided with on-the-fly concordances. Online versions of the Bible translations can easily build KWIC-concordances but not in an equal way. The study shows different approaches to online Bible concordance of the Hungarian translations to be found online and also tries to illustrate bottlenecks of concordance making on the off-line concordance being built to the so called ÚRK Bible (Újonnan Revideált Biblia – Newly Revised Bible). The obstacles in this concordance are connected with terminological and lexicographic approaches as this concordance is based on translations of the keywords of the ESV Bible Concordance.

Published
2022
Full Text
View/download PDF

14. New European Initiatives in Colorectal Cancer Screening: Budapest Declaration. Official Appeal during the Hungarian Presidency of the Council of the European Union under the Auspices of the United European Gastroenterology Federation, the European Association for Gastroenterology and Endoscopy and the Hungarian Society of Gastroenterology

Author

Wittmann, T., Stockbrügger, R.W., Herszenyi, L., Jonkers, D.M.A.E., Molnar, B., Saurin, J. C., Regula, J., Malesci, A., Laghi, L., Pinter, T., Teleky, B., Dite, P., Tulassay, Z., Interne Geneeskunde, and RS: NUTRIM - R2 - Gut-liver homeostasis

Abstract

Colorectal cancer (CRC) is the second most common newly diagnosed cancer and the second most common cause of death in the European Union (EU). CRC is an enormous health and economic burden. Early detection and prevention have the possibility of reducing this burden significantly. Many cancer-associated deaths can be avoided through early detection by high-quality colorectal screening programs followed by appropriate treatment. Under the auspices of the United European Gastroenterology Federation (UEGF), the European Association for Gastroenterology and Endoscopy, the Hungarian Society of Gastroenterology and the Hungarian College of Gastroenterology, the 'Budapest Declaration' (2011) was an accepted official scientific program during the Hungarian Presidency of the Council of the European Union. The Budapest Declaration follows the Munich Declaration (2001), the Brussels Declaration (2007), the Transatlantic Declaration (2009), the Barcelona Declaration (2010), the written declaration of CRC screening, a joint initiative with European Parliamentarians coordinated by the UEGF, and finally, the 'European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis'. The 'Budapest Declaration' together with previous declarations aims to urge the national and supranational healthcare decision makers to launch new Europe-wide initiatives to establish high-quality CRC programs to achieve optimal efficiency in CRC screening. In case of implementation of the proposals, actions and conditions recommended, we can achieve that one of the basic principles of the EU - the chance of equal access - be realized in member states with respect to the prevention of CRC and reduction of cancer-related mortality. To better achieve this goal, we propose to establish an UEGF joint committee, with one participant representing each EU member state to coordinate and supervise the implementation of CRC screening.

Published
2012

15. 1609 Final results from PAVES, a phase 3, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab for locally advanced or metastatic colorectal cancer (LA/mCRC) (NCT00911170)

Author

Pinter, T., primary, Morrow, P.K., additional, Cesas, A., additional, Croitoru, A., additional, Decaestecker, J., additional, Gibbs, P., additional, Hotko, Y., additional, Jassem, J., additional, Kurteva, G., additional, Novotny, J., additional, O'Reilly, S., additional, Salek, T., additional, Khosrowshahi, L., additional, Reiner, M., additional, Klippel, Z., additional, and Blanke, C., additional

Published
2015
Full Text
View/download PDF

22. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.

Author

Sabbatini, P, Harther, P, Scambia, Giovanni, Sehouli, J, Wimbeger, P, Baumann, Kh, Kurzeder, C, Schmalfeldt, B, Cibula, D, Bidzinski, M, Casado, A, Martoni, A, Colombo, N, Holloway, Rw, Selvaggi, L, Del Campo, J, Li, A, Cwiertka, K, Pinter, T, Vermorken, Jb, Scartoni, S, Bertolotti, M, Simonelli, C, Capriati, A, Maggi, Ca, Berek, J, Pfisterer, J., Scambia, Giovanni (ORCID:0000-0003-2758-1063), Sabbatini, P, Harther, P, Scambia, Giovanni, Sehouli, J, Wimbeger, P, Baumann, Kh, Kurzeder, C, Schmalfeldt, B, Cibula, D, Bidzinski, M, Casado, A, Martoni, A, Colombo, N, Holloway, Rw, Selvaggi, L, Del Campo, J, Li, A, Cwiertka, K, Pinter, T, Vermorken, Jb, Scartoni, S, Bertolotti, M, Simonelli, C, Capriati, A, Maggi, Ca, Berek, J, Pfisterer, J., and Scambia, Giovanni (ORCID:0000-0003-2758-1063)

Abstract

PURPOSE: To determine whether abagovomab maintenance therapy prolongs recurrence-free (RFS) and overall survival (OS) in patients with ovarian cancer in first clinical remission. PATIENTS AND METHODS: Patients with International Federation of Gynecology and Obstetrics stage III to IV ovarian cancer in complete clinical remission after primary surgery and platinum- and taxane-based chemotherapy were randomly assigned at a ratio of 2:1 in a phase III, double-blind, placebo-controlled, multicenter study. Abagovomab 2 mg or placebo was administered as 1-mL suspension once every 2 weeks for 6 weeks (induction phase) and then once every 4 weeks (maintenance phase) until recurrence or up to 21 months after random assignment of the last patient. The primary end point was RFS; secondary end points were OS and immunologic response. RESULTS: Characteristics of the 888 patients included: mean age, 56.3 years; Eastern Cooperative Oncology Group performance status, ≤ 1 in > 99% of patients; serous papillary subtype, 81.5%; stage III, 85.9%; and cancer antigen 125 ≤ 35 U/mL after third cycle, 80.9%. Mean exposure to study treatment (± standard deviation) was 449.7 ± 333.08 days. Hazard ratio (HR) of RFS for the treatment group using tumor size categorization (≤ 1 cm, > 1 cm) was 1.099 (95% CI, 0.919 to 1.315; P = .301). HR of OS using tumor size categorization (≤ 1 cm, > 1 cm) was 1.150 (95% CI, 0.872 to 1.518; P = .322). The most frequently reported type of adverse event was an injection site reaction in 445 patients (50.2%), followed by injection site erythema and fatigue in 227 (25.6%) and 212 patients (23.9%), respectively. By the final visit, median anti-anti-idiotypic antibody level was 493,000.0 ng/mL, indicating a robust response. CONCLUSION: Abagovomab administered as repeated monthly injections is safe and induces a measurable immune response. Administration as maintenance therapy for patients with ovarian cancer in first remission does not prolong RFS or OS.

Published
2013

23. Adjuvant trastuzumab in HER2-positive breast cancer.

Author

Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, Arlene, Pawlicki, M., Pinter, T., Valero, V., Liu, M., Sauter, G., von Minckwitz, G., Visco, F., Bee, V., Buyse, M., Bendahmane, B., Tabah-Fisch, I., Lindsay, M., Riva, A., Crown, J., Breast, C., Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, Arlene, Pawlicki, M., Pinter, T., Valero, V., Liu, M., Sauter, G., von Minckwitz, G., Visco, F., Bee, V., Buyse, M., Bendahmane, B., Tabah-Fisch, I., Lindsay, M., Riva, A., Crown, J., and Breast, C.

Abstract

Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab. We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive doxorubicin and cyclophosphamide followed by docetaxel every 3 weeks (AC-T), the same regimen plus 52 weeks of trastuzumab (AC-T plus trastuzumab), or docetaxel and carboplatin plus 52 weeks of trastuzumab (TCH). The primary study end point was disease-free survival. Secondary end points were overall survival and safety. At a median follow-up of 65 months, 656 events triggered this protocol-specified analysis. The estimated disease-free survival rates at 5 years were 75% among patients receiving AC-T, 84% among those receiving AC-T plus trastuzumab, and 81% among those receiving TCH. Estimated rates of overall survival were 87%, 92%, and 91%, respectively. No significant differences in efficacy (disease-free or overall survival) were found between the two trastuzumab regimens, whereas both were superior to AC-T.The rates of congestive heart failure and cardiac dysfunction were significantly higher in the group receiving AC-T plus trastuzumab than in the TCH group (P<0.001). Eight cases of acute leukemia were reported: seven in the groups receiving the anthracycline-based regimens and one in the TCH group subsequent to receiving an anthracycline outside the study. The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. The risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia.

Published
2011

24. Continental vs. tropical breed: Immunity comparison under heat stress conditions utilizing qRT-PCR technique

Author

Fajardo Roland, Kusuma Astuti Putri, Bagi Zoltán, Bodrogi Lilla, Pintér Tímea, Skoda Gabriella, Ohran Husein, Wanjala George, and Kusza Szilvia

Subjects
gene expression, heat stress, hungarian tsigai, il-10, white dorper, Microbiology, QR1-502, Physiology, QP1-981, Zoology, QL1-991
Abstract

Understanding the responses of animals to seasonal heat stress on the genomic level has led to the identification of genes implicated in thermal stress reaction mechanisms. In this study, the relative gene expression of Interleukin-10 (IL-10), an anti-inflammatory cytokine and biomarker for heat stress-mediated immune modulation, was observed during the summer and winter seasons in continental and tropical sheep breeds, namely, Hungarian Indigenous Tsigai and White Dorper, employing quantitative real-time polymerase chain reaction (qRT-PCR). Temperature-humidity indices (THI) were calculated to assess heat stress levels. The results indicate that IL-10 CT-values were significantly higher during the summer, when heat stress prevails, in both sheep breeds compared to winter. While the White Dorper exhibited a higher numerical value for the summer relative gene expression ratio (16.2) compared to the Hungarian Indigenous Tsigai (12.3), no significant differences in CT values were observed between breeds or among sexes. These findings suggest the immune-adaptive characteristics of the two sheep breeds during seasonal heat stress. The variation of IL-10 gene expression levels between the two breeds can be attributed to their geographical origins; the White Dorper emerging from arid subtropical South Africa and the Hungarian Indigenous Tsigai Sheep thriving in the seasonally harsh Carpathian climate for centuries.

Published
2023
Full Text
View/download PDF

25. Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

Author

Finn, RS, primary, Crown, JP, additional, Lang, I, additional, Boer, K, additional, Bondarenko, IM, additional, Kulyk, SO, additional, Ettl, J, additional, Patel, R, additional, Pinter, T, additional, Schmidt, M, additional, Shparyk, Y, additional, Thummala, AR, additional, Voytko, NL, additional, Breazna, A, additional, Kim, ST, additional, Randolph, S, additional, and Slamon, DJ, additional

Published
2012
Full Text
View/download PDF

26. P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer.

Author

Finn, RS, primary, Crown, JP, additional, Boer, K, additional, Lang, I, additional, Parikh, RJ, additional, Patel, R, additional, Schmidt, M, additional, Hagenstad, C, additional, Lim, H, additional, Pinter, T, additional, Amadori, D, additional, Chan, D, additional, Dichmann, RA, additional, Walshe, J, additional, Breazna, A, additional, Kim, ST, additional, Randolph, S, additional, and Slamon, DJ, additional

Published
2011
Full Text
View/download PDF

27. A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.

Author

Finn, R. S., primary, Boer, K., additional, Lang, I., additional, Parikh, R. J., additional, Patel, R., additional, Schmidt, M., additional, Hagenstad, C. T., additional, Lim, H. J., additional, Pinter, T., additional, Amadori, D., additional, Chan, D., additional, Dichmann, R., additional, Kim, S. T., additional, Randolph, S., additional, Slamon, D. J., additional, and Crown, J. P., additional

Published
2011
Full Text
View/download PDF

28. Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer

Author

Martin, M, primary, Mackey, J, additional, Pienkowski, T, additional, Rolski, J, additional, Guastalla, J-P, additional, Sami, A, additional, Glaspy, J, additional, Juhos, E, additional, Wardley, A, additional, Fornander, T, additional, Hainsworth, J, additional, Coleman, R, additional, Modiano, M, additional, Vinholes, J, additional, Pinter, T, additional, Childs, B, additional, Roessner, M, additional, Wilson, V, additional, Rupin, M, additional, and Vogel, C, additional

Published
2010
Full Text
View/download PDF

32. Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial.

Author

Sabbatini, P., primary, Berek, J. S., additional, Casado, A., additional, Cwiertka, K., additional, Pinter, T., additional, Pluzanska, A., additional, Scambia, G., additional, Pujade-Lauraine, E., additional, Vermorken, J. B., additional, and Pfisterer, J., additional

Published
2010
Full Text
View/download PDF

33. CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC).

Author

Mackey, J., primary, Hurvitz, S., additional, Crown, J., additional, Forbes, J., additional, Roché, H., additional, Pinter, T., additional, Eiermann, W., additional, Kennedy, M., additional, Priou, F., additional, Provencher, L., additional, Adrover, E., additional, Pienkowski, T., additional, Houé, V., additional, Rupin, M., additional, and Martin, M., additional

Published
2009
Full Text
View/download PDF

44. A Randomised, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Ondansetron (GR38032F) plus Dexamethasone with Metoclopramide plus Dexamethasone in the Prophylaxis of Nausea and Emesis Induced by Carboplatin Chemotherapy

Author

du Bois, A., primary, McKenna, C.J., additional, Andersson, H., additional, Lahousen, M., additional, Kitchener, H., additional, Pinter, T., additional, Capstick, V., additional, and Wilkinson, J.R., additional

Published
1997
Full Text
View/download PDF

46. Gas Emissions in Combustion of Biofuel

Author

Vitázek Ivan, Klúčik Janko, Pinter Tomáš, and Mikulová Zuzana

Subjects
heat source, solid biofuel, emissions, briquette, frewood, Agriculture (General), S1-972
Abstract

Nowadays, biomass or more precisely biofuel is more and more being exploited as a substitute for fossil fuels for heating as well as for example for heating a drying environment. This contribution focuses on assessing a heat source by combusting various types of solid biofuels. It is a boiler VIGAS 25 with AK 2000 regulation for heating a family house. Gaseous emissions were measured using a device TESTO 330-2LL. Firewood, peat briquettes, bark briquettes and hardwood briquettes were burnt. Results of experimental measurements concerning the production of gaseous emissions are processed in tables and graphs depending on boiler performance and combustion time.

Published
2014
Full Text
View/download PDF

49. The economic and social challenges of European integration: The case of the Western Balkans

Author

Pintér Tibor

Subjects
institutional development, economic integration, european integration, enlargement process, competitiveness, foreign economic policy, regional integration, historical, Production management. Operations management, TS155-194, Personnel management. Employment management, HF5549-5549.5
Abstract

The enlargement of the European Union is a complex, horizontally and vertically interrelated subject. The European integration is one of the most determining socio-economic processes of the past decades. The European Union’s enlargement and external economic policy towards the Western Balkans - and according to the Union’s terminology Serbia may also be listed here - requires the implementation of a different approach because of the special evolutionary heritage. The integration of the region can take a fairly long time because not only the acceptance of economic legislation is involved. The contemporary economic and financial crisis revealed a great deal of controversies in this issue as well. The applied enlargement framework of the EU has plenty of features, cutting into the so-called deep layers of a nation state. The changes in these deep layers - according to the results of the new institutional economics - come only after decades off. What kind of connection can be observed between institutional development and EU enlargement? Is the applied framework responsive enough to these layers? After the presentation of the measurement opportunities and indicators of the institutional development, we focus on the data which are at disposal by the international qualifier organizations. Several international institutions attempt to measure the institutional development of a nation-state, with the help of an index to compress. These evaluation tools can serve as additional instruments in the measurement of the so-called integration maturity studies. However, the quest for the measurability and comparability should not lead to an oversimplification.

Published
2014

50. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel

Author

Durbecq, V., Paesmans, M., Cardoso, F., Desmedt, C., Di Leo, A., Chan, S., Friedrich, K., Pinter, T., Belle, S., Murray, E., Bodrogi, I., Euan Walpole, Lesperance, B., Korec, S., Crown, J., Simmonds, P., Perren, Tj, Leroy, Jy, Rouas, G., Sotiriou, C., Piccart, M., and Larsimont, D.

Subjects
Adult, Receptor, ErbB-2, Breast Neoplasms, Docetaxel, Middle Aged, Immunohistochemistry, DNA-Binding Proteins, DNA Topoisomerases, Type II, Treatment Outcome, Antigens, Neoplasm, Doxorubicin, Cell Line, Tumor, Multivariate Analysis, Biomarkers, Tumor, Odds Ratio, Humans, Female, Taxoids, Poly-ADP-Ribose Binding Proteins, Aged, Retrospective Studies
Abstract

The predictive value of topoisomerase-II alpha (topo-II) has been evaluated in advanced breast cancer patients randomly treated with single-agent doxorubicin or docetaxel.Primary tumor samples from patients enrolled in a randomized, phase III clinical trial comparing single-agent doxorubicin (75 mg/m(2) q3wks) with docetaxel (100 mg/m(2) q3wks) were collected and topo-II status was evaluated by immunohistochemistry (clone KiS1).Topo-II status was evaluated in 108 samples, 55 (51%) in the doxorubicin arm and 53 (49%) in the docetaxel arm. An increment of 10% in cells expressing topo-II is associated with a statistically significant odds ratio (OR; 95% confidence interval) of 1.09 (1.03-1.15; P = 0.002) for overall response to doxorubicin versus 1.002 (0.94-1.07; P = 0.95) in the docetaxel arm. With increasing topo-II, the favorable OR for overall response to docetaxel compared with doxorubicin decreases to become not significant in patients with topo-II tumor content10%. In a multivariate analysis, (a) HER-2 status seems positively correlated with overall response to chemotherapy (OR, 2.34; 95% confidence interval, 0.87-6.27; P = 0.09). (b) Overall response to doxorubicin is significantly lower than overall response to docetaxel (OR, 0.17; 95% confidence interval, 0.04-0.64; P = 0.009) but with a significant interaction term for doxorubicin-treated patients with topo-II tumor content10% (OR, 8.31; 95% confidence interval, 1.86-37.03; P = 0.05).(a) Topo-II overexpression confers a higher probability of response in the doxorubicin arm only. (b) Despite being a small retrospective study, this study is in line with previously reported studies and the hypotheses raised are now being tested in a prospective neoadjuvant trial.

Catalog

Books, media, physical & digital resources
See catalog results